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Edited by Veli-Pekka LehtoAbstract Under normoxic conditions the alpha-subunit of hy-
poxia-inducible factor (HIF-1a) protein is targeted for degrada-
tion by the von Hippel-Lindau (VHL) tumor suppressor protein
acting as an E3 ubiquitin ligase. Recently, we developed a hypox-
ia-targeting protein, TOP3, which consisted of procaspase-3
with the VHL-mediated protein destruction motif of HIF-1a.
This design enables procaspase-3 to be regulated similarly with
HIF-1a, being degraded under normoxia while stabilized under
hypoxia. Furthermore, stabilized TOP3 was cleaved by the hyp-
oxic stress-induced endogenous caspases and thus the procas-
pase-3 was converted to active caspase-3 speciﬁcally under
hypoxic conditions. These data demonstrated that the VHL-
mediated protein destruction motif of HIF-1a endowed procas-
pase-3 with hypoxia-speciﬁc cytotoxicity.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Hypoxia-inducible factor (HIF) is a transcriptional complex
that mediates a broad range of cellular and systemic responses
to hypoxia [1]. HIF-1 is a heterodimer composed of a and b
subunits, and a subunit of HIF-1 (HIF-1a) is regulated in an
oxygen-dependent manner at the post-translational level [2–
4]. HIF-1a contains oxygen-dependent degradation (ODD)
domains, which contains proline residues, proline-402 and pro-
line-564. In normoxia, HIF-1a is hydroxylated at these proline
residues by prolyl-4-hydroxylases [5,6]. The modiﬁcation accel-
erates the interaction of the HIF-1a protein with the von Hip-
pel-Lindau (VHL) tumor suppressor protein, resulting in the
rapid ubiquitination and subsequent degradation of the pro-
tein by the 26S proteasome [7–10].
Recently, we screened ODD domain mutants of human
HIF-1a protein and determined the ODD548–603, which en-
dowed fusion proteins with suﬃcient oxygen-dependent degra-
dation regulation [11]. In order to speciﬁcally eradicate
HIF-1a-expressing hypoxic cells in solid tumors, we con-*Corresponding author. Fax: +81 75 771 9749.
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doi:10.1016/j.febslet.2006.09.025structed procaspase-3 fused with ODD548–603 and HIV-Tat
protein-transduction domain (PTD). The ﬁnal product was
named TOP3 (Tat-ODD-Procaspase-3) [11–14]. The HIV-Tat
PTD domain is derived from human immunodeﬁciency virus
type-1 Tat protein and eﬃciently delivers TOP3 to any tissue
in vivo. The procaspase-3 comes from human caspase-3 pro-
tein [15] and confers cytocidal activity to TOP3. We already re-
ported that TOP3 had anti-tumor activity in xenografts model
with various cancer cells [11–14] and induced apoptosis to hyp-
oxic tumor cells in xenografts [14].
In the present study, we clarify the mechanism of TOP3 acti-
vation and conﬁrm its hypoxia-speciﬁc cytotoxity.2. Materials and methods
2.1. Cell culture and hypoxic treatment in vitro
CFPAC-1 and MIA PaCa-2 human pancreatic cancer cell lines,
HeLa human cervical epithelial adenocarcinoma cell line, A549 human
lung adenocarcinoma cell line, WiDr human colorectal adenocarci-
noma cell line and 786-O human renal cell carcinoma cell line were
purchased from the American Type Culture Collection. HeLa/EF-
Luc and HeLa/5HRE-Luc cell clones were isolated as described previ-
ously [14]. WT8, a 786-O cell clone stably transfected with a plasmid
coding hemagglutinin (HA)-tagged VHL, was a kind gift from Dr.
William G. Kaelin Jr. [16]. CFPAC-1 was maintained as described pre-
viously [11], and the other cells were maintained at 37 C in 5% FBS-
Dulbecco’s modiﬁed Eagle’s medium (Nacalai Tesque, Kyoto, Japan)
supplemented with penicillin (100 units/ml) and streptomycin (100 lg/
ml).
Hypoxic condition of <0.02% of oxygen tension was attained by the
use of a Bactron Anaerobic Chamber, BACLITE-1 (Sheldon Manu-
facturing Inc., Cornelius, OR). Cells were incubated in the chamber
for at least 6 h before various treatments.
2.2. Formulation of TOP3 fusion protein
The Tat-ODD-Procaspase-3 fusion protein (TOP3) was prepared
and dissolved in 10 mM Tris–HCl buﬀer (pH 8.0), as described previ-
ously [11]. The ﬁnal concentration of TOP3 preparation was 15 lg/ml
for in vitro experiments if not indicated, and 10 mM Tris–HCl (pH 8.0)
was used as the buﬀer in both in vivo and in vitro experiments if not
indicated.
2.3. Experimental procedures for analyses of TOP3 activation in vitro
Cells were pre-incubated under aerobic or hypoxic condition for 6 h,
added with TOP3, and incubated further for 20 h before analyses.
As for the Western blot analysis, cells were seeded at 1 · 105 cells/
well in a 6-well plate, treated as above and the lysates were prepared
by suspending cells from each well in 100 ll of 1 · loading buﬀer.
Twenty ll of the lysate was electrophoresed per lane on a 15% (forblished by Elsevier B.V. All rights reserved.
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acrylamide gel. TOP3/caspase-3, VHL and HIF-1a were detected by
polyclonal anti-caspase-3 antibody (Cell Signaling Technology Inc.,
Osaka, Japan), monoclonal anti-HA antibody (Roche Diagnostics
Japan, Tokyo, Japan) and monoclonal anti-HIF-1a antibody (BD
Bioscience Pharmingen, San Diego, CA), respectively. The polyclonal
and the monoclonal primary antibodies were then reacted with anti-
rabbit and anti-mouse IgG horseradish peroxidase linked antibodies
(Amersham Biosciences Corp., Piscataway, NJ), respectively. Detec-
tion was carried out with a chemiluminescence-based method using
the ECL-PLUS system (Amersham Biosciences Corp.).
As for the DNA fragmentation analysis, genomic DNA was isolated
from 6 · 105 cells with Quick Apoptotic Ladder Detection Kit (BioVi-
sion Research Products, Mountain View, CA). DNA was electropho-
resed in a 1.5% agarose gel.
As for the FACS analysis, the cells were harvested, gently suspended
in PBS and mixed with equal volume of 2 · hypotonic ﬂuorochrome
solution (100 lg/ml propidium iodide in 0.2% sodium citrate–0.2% Tri-
ton X-100) immediately before the analysis with a ﬂow cytometry using
CELLQuest (BD Biosciences, Franklin Lakes, NJ).
As for the analysis of caspase-3 after TOP-3 treatment, the cells were
seeded at 2 · 104 cells/well in a 24-well plate, pre-incubated for 16 h
and treated with TOP3 for 0, 2, 4, 6 or 8 h. As for the analysis of
endogenous capsase-3 and -9 activities, similarly seeded cells were cul-
tured with the medium, which was pre-exposed to hypoxic conditions.
Then the cells were incubated under hypoxic or aerobic conditions and
harvested after indicated time of incubation. Caspase-3 and -9 activi-Fig. 1. Hypoxia-dependent stabilization and activation of TOP3 in vitro. (A)
TOP3 (+; lanes 2 and 4) under aerobic (lanes 1 and 2) or hypoxic (lanes 3 and
proteins in the cells were analyzed by Western blotting with a polyclonal anti
major derivative proteins and endogenous caspase-3 are indicated by arrowhe
1a (lower panel) proteins of the lanes 2–4 to the lane 1 are indicated below ea
conditions for indicated period of time and then cell lysates were prepared. C
and relative caspase activities to the 0 h are indicated. (C) CFPAC-1 cells were
for 16 h and then treated with TOP3 or the buﬀer for the indicated period of
was measured. TOP3-derived caspase-3 activity was calculated using the follo
50 lg of the buﬀer-treated cells). Results are the means of three independent
TOP3 (+) for 20 h under hypoxic conditions. Then the genomic DNA was ities in 50 ll lysates were measured by using Colorimetric Protease
Assay Kit according to the manufacturer’s instructions (MBL,
Nagoya, Japan). The experiments were done in triplicate and the mean
of OD405nm/50 lg was calculated.3. Results
3.1. Hypoxia-dependent activation of TOP3
We previously showed citocidal eﬀect of TOP3 on hypoxic
cells in the xenografts of a human pancreatic cancer cell line
[11,14]. TOP3 was designed to be degraded in normoxic cells
through the function of ODD domain of human HIF-1a pro-
tein which is sensitive to the VHL-mediated destruction in nor-
moxia. The design allows the conversion of the procaspase-3
domain to active caspase-3 under hypoxia, executing apoptotic
killing of the cells.
These expectations were tested as follows. Firstly, the stabil-
ity of TOP3 was compared with that of HIF-1a protein under
aerobic and hypoxic conditions (Fig. 1A). CFPAC-1 cells were
cultured under aerobic (lanes 1 and 2) and hypoxic (lanes 3 and
4) conditions and the protein levels of TOP3 and HIF-1a were
tested with (lanes 2 and 4) or without (lanes 1 and 3) additionCFPAC-1 cells were treated with the buﬀer only (; lanes 1 and 3) or
4) conditions for 20 h. TOP3 (upper panel) and HIF-1a (lower panel)
-caspase-3 and a monoclonal HIF-1a antibody, respectively. TOP3, its
ads. The relative density of the bands of TOP3 (upper panel) and HIF-
ch panel, respectively. (B) CFPAC-1 cells were cultured under hypoxic
aspase-9 (left) and -3 (right) activities in the cell lysates were measured
cultured under aerobic (open bars) and hypoxic (gray bars) conditions
time. Total cell lysates were prepared and then OD405nm of the lysates
wing formula: (OD405nm/50 lg of the TOP3-treated cells)  (OD405nm/
experiments ± S.D. (D) The cells were treated with the buﬀer () and
solated and analyzed by electrophoresis with a 1.5% agarose gel.
Fig. 2. VHL-dependent ODD regulation of TOP3. 786-O (VHL-
deﬁcient renal cell carcinoma cell line) and WT8 (HA-tagged VHL-
transfectant clone of 786-O) were treated with the buﬀer only (; lanes
1, 3, 5 and 7) or TOP3 (+; lanes 2, 4, 6 and 8) under aerobic (lanes 1–4)
or hypoxic (lanes 5–8) conditions. (A) TOP3 (upper panel) and VHL
5720 H. Harada et al. / FEBS Letters 580 (2006) 5718–5722of TOP3. Hypoxic treatment markedly stabilized TOP3 and
the protein level was elevated more than 14-fold (Fig. 1A
upper panel, lane 2 vs. lane 4). In the same cell preparation,
a comparable 14-fold increase was noted for HIF-1a as well
(Fig. 1A lower panel, lane 2 vs. lane 4). The control protein
without the ODD domain was unaﬀected by the oxygen ten-
sion of the culture (data not shown). These results demonstrate
that the stability of TOP3 is sensitive to oxygen concentration
as designed.
When CFPAC-1 cells were tested, endogenous caspase-9, the
principal caspase in the pathway of mitochondria mediated
apoptosis [17], gradually increased and reached the peak after
18 h under hypoxia (Fig. 1B; left panel). However, endogenous
caspase-3 activity increased only marginally during the obser-
vation period (Fig. 1B; right panel). On the other hand, addi-
tion of TOP-3 increased the total caspase-3 activity more than
20-fold when the culture was kept under hypoxia (Fig. 1C).
Under this condition, TOP3 induced DNA fragmentation of
the cells (Fig. 1D). These results demonstrate that the increase
in caspase-3 activity of TOP3-treated cells under hypoxia was
due to stabilization and conversion of TOP3 to active caspase-
3, resulting in DNA fragmentation. Hypoxia-speciﬁc apoptosis
induction by TOP3 was also observed other human cancer cell
lines such as CFPAC-1, MIA PaCa-2, A549 and WiDr (data
not shown), indicating that the function of TOP3 is not cell
line-speciﬁc.(lower panel) proteins in total cell lysate prepared from each culture
were detected by western blot analysis with anti-caspase-3 polyclonal
and anti-HA monoclonal antibodies, respectively. (B) DNA contents
of these cells were analyzed by ﬂow cytometry and % of population in
sub-G1 fraction is indicated as % of dead cell.3.2. VHL-mediated degradation of TOP3
The above observations demonstrate destruction and stabil-
ization of TOP-3 paralleled with those of HIF-1a protein, sug-
gesting that both proteins are under regulation of the VHL
mediated degradation system. This was tested by the use of
786-O cells which lacked functional VHL and therefore ubiq-
uitination-mediated degradation through ODD domain does
not take place in this cell line. As a positive control, VHL
reconstituted WT8 cells were used [16]. In these cells, TOP3
was stabilized if VHL was not expressed (Fig. 2A; upper and
lower panels, lane 2) and degraded if VHL was reconstituted
(Fig. 2A; upper and lower panels, lane 4). The TOP3 was sta-
bilized (Fig. 2A; upper panel, lanes 6 and 8) and enhanced
apoptosis of hypoxic cells (Fig. 2B; lanes 6 and 8) regardless
of the VHL status (Fig. 2A; lower panel, lanes 5–8). In con-
trast, TOP3 did not induce apoptosis regardless of VHL status
of the cells as long as the cells were under aerobic conditions
(Fig. 2B; lanes 2 and 4).
These results indicate following two. Firstly, the degradation
of TOP3 under aerobic conditions is dependent on the VHL
function, indicating that it is regulated by the same VHL-
mediated protein degradation mechanism as the one of HIF-
1a [7–10]. Secondly, the stabilized TOP3 still requires another
step to induce apoptosis and this step requires hypoxia.3.3. Enhancement of hypoxia-induced apoptosis in various
cancer cell lines by TOP3
The requirement of hypoxia for the TOP3-induced apoptosis
suggests that the cleavage mediated conversion of TOP to
caspase-3 is likely to be executed by the endogenous caspases
which are activated by hypoxic stress. To assess this possibil-
ity, human cancer cell lines, CFPAC-1, MIA PaCa-2, and
A549 were treated with TOP3 under hypoxia or normoxia.
Morphological observation demonstrated that TOP3 treat-ment induced cytotoxicity speciﬁcally under hypoxia (Fig. 3A).
Moreover, FACS analysis conﬁrmed that TOP3 treatment un-
der hypoxic conditions induced degradation of genome DNA
as suggested by the increase in the sub-G1 fraction, indicative
of the caspase-3 mediated apoptosis of the cells (Fig. 3B).
Sub-G1 fraction increased in TOP3 treated CFPAC-1, MIA
PaCa-2 and A549 cells under hypoxic conditions by around
10-fold, and were 28.0 ± 2.1%, 27.5 ± 3.8% and 56.5 ± 0.8%,
respectively.4. Discussion
In the present study, we examined the molecular mechanism
of activation of procaspase-3 fused with ODD548–603, which
has VHL-mediated protein destruction motif of HIF-1a con-
taining only 564-proline residue. The results are summarized
in Fig. 4.
The ODD domain of HIF-1a including the 564-proline res-
idue physically interacts with VHL which plays a key role in
the degradation of the protein through the ubiquitin-protea-
some pathway [3–10]. The TOP3 carries the ODD548–603
domain and therefore, its ODD regulation was expected to
be dependent on VHL expression. Indeed, TOP3 was found
to be stable in VHL-deﬁcient 786-O cells even under aerobic
conditions (Fig. 2A). These results indicate that TOP3 behaves
similarly as HIF-1a and is stabilized in the hypoxic cells
in vitro. In our experiments using xenografts, at-ODD-b-gal-
actosidase injected intraperitoneally was speciﬁcally detected
in the hypoxic regions of tumor xenografts [11]. Present study
Fig. 3. Enhancement of hypoxia-induced apoptosis by TOP3. CFPAC-1, MIA PaCa-2 and A549 cells were treated with TOP3 (+) or the buﬀer only
() for 20 h under aerobic or hypoxic conditions. (A) The morphologies of the cells were observed under an inverted microscope just before FACS
analysis. Bar = 200 lm. (B) DNA contents of these cells were analyzed by ﬂow cytometry. % of population in sub-G1 fraction is indicated in each
chart. The experiments were done in triplicate and representative photographs (A) and charts (B) are shown.
Fig. 4. Mechanism of hypoxia-speciﬁc cytotoxicity of TOP3. TOP3
enters in cells by the function of protein transduction domain (PTD) of
HIV TAT protein. (1) In hypoxic tumor cells, endogenous caspases are
activated to some extent (Fig. 1B). (2) When TOP3 enters in hypoxic
tumor cells, TOP3 is cleaved (Fig. 1A, lane 4). (3) Activity of caspase-3
in TOP3-treated hypoxic tumor cells signiﬁcantly increases (Fig. 1C).
(4) DNA fragmentation (Figs. 1D and 3B) is induced and TOP3-
treated hypoxic tumor cells undergo apoptosis (Fig. 3). The ODD of
TOP3 is the VHL-mediated protein destruction motif of HIF-1a and
TOP3 is degraded by VHL-mediated system under normoxia (Fig. 2).
(5) When TOP3 enters in aerobic cells, TOP3 is recognized by VHL
and (6) degraded through ubiquitin-proteasome system.
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ilarly as HIF-1a via VHL-mediated protein destruction motif
of HIF-1a in vitro.
Because TOP3 is composed of a dormant form of caspase-3,
it has to be cleaved to become active form. That is, stabiliza-
tion of TOP3 itself cannot induce apoptosis. Indeed, TOP3
was stabilized in 786-O cells under normoxia but did not in-
duce cell death (Fig. 2C). The endogenous caspase activities
are brought about by a hypoxic stress (Fig. 1B). Although
the major apoptosis pathway induced by hypoxic stress is the
mitochondria-mediated ‘intrinsic’ pathway, in which caspase-
9 plays a major role, recent studies suggest the involvement
of both the intrinsic and the death receptor-mediated ‘extrin-
sic’ pathways in hypoxia-induced apoptosis [18]. TOP3 eﬃ-
ciently enhance the preexisting apoptotic signal leading to
more than 20-fold increases of caspase-3 activity (Fig. 1C)
and induced DNA fragmentation (Fig. 1D) and cell death
(Figs. 2 and 3). All of these characteristics must have contrib-
uted not only to the speciﬁc targeting of HIF-1a-expressing/
hypoxic tumor cells but also to minimizing the obvious side ef-
fect to normal tissues in our in vivo experiments [11–14].
It has been reported that hypoxia-induced apoptosis de-
pends on wild-type p53 to a large extent [19–22] and that in-
creased p53 induces apoptosis through a pathway including
Apaf-1 and caspase-9 [23]. Thus the extent of hypoxia-induced
apoptosis might diﬀer due to p53 status. Interestingly, under
hypoxic conditions A549 cells, which possess wild type p53
[24], underwent apoptosis to a larger extent than CFPAC-1
5722 H. Harada et al. / FEBS Letters 580 (2006) 5718–5722and MIA PaCa-2 cells, which possess mutant type p53 ([25]
and Fig. 3).
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